Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging
Reference10 articles.
1. Osayande E, Carika F, Gerrit E. Technetium 99m PSMA superscan mimicking a bone scan gone wrong. Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s13139-022-00749-3.
2. Moghadam SZ, Askari E, Divband G, Shakeri S, Aryana K. Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: a single center study. Rev Esp Med Nucl Imagen Mol. 2021. https://doi.org/10.1016/j.remnie.2021.05.005.
3. Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, et al. Intraindividual comparison of 99mTc-methylene diphosphonate and prostate-specific membrane antigen ligand 99mTc-MIP-1427 in patients with osseous metastasized prostate cancer. J Nucl Med. 2018;59:1373–9.
4. Aryana K, Salek R, Divband G. 177Lu-prostate-specific membrane antigen super scan and good response even after 1 cycle of radioligand therapy. Clin Nucl Med. 2018;43:273–5.
5. Novartis (2022) Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer. In: Novartis media releases. 2022. https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer. Accessed 20 Apr 2022.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献